Quanex Building Products CORP
For the period ended Jul 31, 2024. Filed Sep 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jul 31, 2024 · Filed Sep 6, 2024
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2024-04-30; filed 2024-06-07.
0001423221-24-000009
Item 1A. Risk FactorsOther InformationCurrent report: 10-Q
Period ended 2024-07-31; filed 2024-09-06.
0001423221-24-000012
Item 1A. Risk FactorsOther InformationThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 15 previous paragraphs and 9 current paragraphs.
7 unchanged; 1 reworded; 1 added; 7 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (1)
Current report
George Wilson our Chairman, President and CEO, adopted a Rule 10b5-1 trading arrangement on June 11, 2024. Under this arrangement, a total of 37,800 shares of our common stock may be sold, subject to certain conditions, before the plan expires on November 30, 2026.
Removed paragraphs (7)
Previous report
Quanex may fail to consummate the Tyman Acquisition or may not consummate the Tyman Acquisition on the terms or timing described herein.
Previous report
It is currently anticipated that the Tyman Acquisition will be consummated in the second half of calendar year 2024. Completion of the Tyman Acquisition is subject to, among other things, the receipt of applicable shareholder approvals by both Tyman shareholders and Quanex stockholders, regulatory approvals and other customary closing conditions for the acquisition of a UK public company. As a result, the possible timing and likelihood of completion are uncertain, and, accordingly, there can be no assurance that the Tyman Acquisition will be completed on the expected terms, on the anticipated schedule, or at all.
Previous report
If the Tyman Acquisition is not consummated, we could be subject to a number of risks that may adversely affect our business and the market price of Quanex common stock, including:
Previous report
•we will be required to pay costs relating to the Tyman Acquisition such as legal, accounting, financial advisory and printing fees, whether or not the Tyman Acquisition is consummated;
Previous report
•time and resources committed by our management to matters relating to the Tyman Acquisition could otherwise have been devoted to pursuing other beneficial opportunities; and
Previous report
•we would not realize the benefits we expect to realize from consummating the Tyman Acquisition.
Previous report
We cannot provide any assurance that the Tyman Acquisition will be consummated or that there will not be a delay in the consummation of the Tyman Acquisition. If the Tyman Acquisition is not consummated, our reputation in our industry and in the investment community could be damaged, and the market price of our common stock could decline.
Reworded paragraphs (1)
Previous wording
During the three months ended April 30, 2024, none of our directors or executive officers adopted orterminated any contract, instruction or written plan for the purchase or sale of our securities to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.”
Current wording
During the three months ended July 31, 2024, none of our directors or executive officers adopted orterminated any contract, instruction or written plan for the purchase or sale of our securities to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement,” except as follows: